DDIT3 and diffuse large B-cell lymphoma: For example, the ECOG‐ACRIN‐1412 trial, which compared lenalidomide in combination with R‐CHOP to R‐CHOP alone, found that the addition of lenalidomide was associated with improved progression‐free survival (PFS) in patients with ABC subtype DLBCL, but not in patients with the GCB subtype [22].